BIRDS

Piramal Pharma solutions with strong development and regulatory capabilities, backed by accredited manufacturing sites, help customers in Late Pharmaceutical Life Cycle management of their products.

Piramal Pharma Solutions offers HPAPI development and contract services through its FDA approved cGMP facility in Riverview, MI (USA). It offers full range of scale & containment options for HPAPIs.

Piramal Pharma Solutions provide manufacture and supply of Active Pharmaceutical Ingredients on an integrated manufacturing model across North America, Europe and Asia.

Piramal Pharma Solutions offers antibody drug conjugate process development and scale-up through highly experienced team that has been working on ADCs over one decade. Find out more here.

Vitamins are organic substances required in small quantities for normal health and growth of an indi

Micronutrient deficiency is a lack of essential vitamins and minerals which are required in small am

Piramal Pharma Solutions offers best-in-class services for mg to gm scale with the help of medicinal chemistry requirements. Specialized team at Piramal Discovery Solutions is proficient in developing methodologies

Piramal Pharma Solutions In-Vitro facilities offer ADME services for providing faster & improved decision-making for chemistry clients. We offer economical customized and standardized assays as per the client’s requirement for ADME parameters.

Piramal Pharma Solutions fully equipped kilo lab service allows for speedy advancement of scalable and robust chemical processes using progressive process technique to provide a quick supply in the early phase of the improvement.

"Piramal Pharma Solutions Analytical Chemistry Services offers Chiral purification-gram scale by Super Critical Fluid Chromatography, Prep HPLC Purification services, Impurity isolation and characterization & much more. we have committed analytical suites containing advanced analytical equipment and a team of over 55 analytical scientists. "

We provide Route scouting services with API development which minimize the waste and the cost OF API

Piramal Pharma R&D services provide pharmaceutical intermediated and API development for new drug discovery and development solutions to the clients worldwide.

Piramal Pharma Solutions experts offers pre-formulation studies in drug formulation with valuable information and suggestions to handle a wide range of compounds.

Piramal Pharma Solutions offers wide range of clinical analytical support services, including analytical method development, validation and transfer and also API chemical and physical properties.

Piramal Pharma Solutions regulatory services provide expert clinical and regulatory support in all phases of global drug development programs that include regulatory support of New Chemical Entity development.

Piramal Pharma Solutions offer specialized services in the area of Clinical Trial Supply management. We provideprovide a range of clinical trial services that include clinical trial manufacturing, packaging and supply of APIs and Formulations. The services are offered for molecules in Phase I-III clinical trials

Piramal Pharma Solutions, supply and distribute commercial formulations of Oral Solid dosage forms to the leading biotech and pharmaceutical companies worldwide.

Sterile Manufacturing facility located in Lexington, Kentucky in the USA offers cGMP manufacturing of a wide range of injectable products that also includes process development and optimization.

Piramal Pharma Solutions offer Commercial APIs - Active Pharmaceutical Ingredients, API launching products and APIs under development products for the pharmaceutical industry needs.

Vitamin A (Retinol) is essential for the maintenance of epithelial tissues and deficiency of Vitamin

As a gut-restricted, nonabsorbed therapy, polymeric bile acid sequestrants (BAS) play an important role in managing hyperlipidemia and hyperglycemia. Similarly, nonabsorbable sequestrants of dietary phosphate have been used for the management of hyperphosphatemia in end-stage renal disease. To evaluate the potential utility of such polymer sequestrants to treat type 2 diabetes (T2D) and its associated renal and cardiovascular complications, we synthesized a novel polymeric sequestrant, SAR442357, possessing optimized bile acid (BA) and phosphate sequestration characteristics. Long-term treatment of T2D obese cZucker fatty/Spontaneously hypertensive heart failure F1 hybrid (ZSF1) with SAR442357 resulted in enhanced sequestration of BAs and phosphate in the gut, improved glycemic control, lowering of serum cholesterol, and attenuation of diabetic kidney disease (DKD) progression. In comparison, colesevelam, a BAS with poor phosphate binding properties, did not prevent DKD progression, whereas losartan, an angiotensin II receptor blocker that is widely used to treat DKD, showed no effect on hyperglycemia. Analysis of hepatic gene expression levels of the animals treated with SAR442357 revealed upregulation of genes responsible for the biosynthesis of cholesterol and BAs, providing clear evidence of target engagement and mode of action of the new sequestrant. Additional hepatic gene expression pathway changes were indicative of an interruption of the enterohepatic BA cycle. Histopathological analysis of ZSF1 rat kidneys treated with SAR442357 further supported its nephroprotective properties. Collectively, these findings reveal the pharmacological benefit of simultaneous sequestration of BAs and phosphate in treating T2D and its associated comorbidities and cardiovascular complications. SIGNIFICANCE STATEMENT A new nonabsorbed polymeric sequestrant with optimum phosphate and bile salt sequestration properties was developed as a treatment option for DKD. The new polymeric sequestrant offered combined pharmacological benefits including glucose regulation, lipid lowering, and attenuation of DKD progression in a single therapeutic agent.

As a gut-restricted non-absorbed therapy, polymeric bile acid sequestrants (BAS) play an important role in managing hyperlipidemia and hyperglycemia. Similarly, non-absorbable sequestrants of dietary phosphate have been used for the management of hyperphosphatemia in end stage renal disease. To evaluate the potential utility of such polymer sequestrants to treat type 2 diabetes (T2D) and its associated renal and cardiovascular complications, we synthesized a novel polymeric sequestrant, SAR442357 possessing optimized bile acid (BA) and phosphate sequestration characteristics. Long-term treatment of T2D obese ZSF1 rats with SAR442357 resulted in enhanced sequestration of BAs and phosphate in the gut, improved glycemic control, lowering plasma cholesterol and triglycerides and attenuated diabetic kidney disease (DKD) progression. In comparison, colesevelam, a BAS with poor phosphate binding property did not prevent DKD progression, while losartan, an angiotensin II receptor blocker that is widely used to treat DKD, showed no effect on hyperglycemia. Analysis of hepatic gene expression levels of the animals treated with SAR442357 revealed upregulation of genes responsible for the biosynthesis of cholesterol and BAs, providing clear evidence of target engagement and mode of action of the new sequestrant. Additional hepatic gene expression pathway changes were indicative that there was interruption of the enterohepatic BA cycle. Histopathological analysis of ZSF1 rat kidneys treated with SAR442357 further supported its nephroprotective properties. Collectively, these findings reveal the pharmacological benefit of simultaneous sequestration of BAs and phosphate in treating T2D and its associated comorbidities and cardiovascular complications. Significance Statement A new non-absorbed polymeric sequestrant with optimum phosphate and bile salt sequestration properties was developed as a treatment option for DKD. The new polymeric sequestrant offered combined pharmacological benefits including glucose regulation, lipid lowering and attenuation of DKD progression in a single therapeutic agent.

This week, we'll wrap up the diabetes pills series with a focus on two lesser-known (and lesser-used) diabetes medicines.